about
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapyIpilimumab plus dacarbazine for previously untreated metastatic melanomaDermcidin: a novel human antibiotic peptide secreted by sweat glandsDacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'Improved survival with MEK inhibition in BRAF-mutated melanomaPrognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up.Improving melanoma classification by integrating genetic and morphologic featuresA randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.Screening for skin cancer in bank and insurance employees: risk profile and correlation of self and physician's assessment.Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.Imaging characteristics of cardiac metastases in patients with malignant melanomaNon-AIDS associated Kaposi's sarcoma: clinical features and treatment outcomeβ-Catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistanceAcral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients.Prognosis of sentinel node staged patients with primary cutaneous melanomaPrimary localization and tumor thickness as prognostic factors of survival in patients with mucosal melanoma.Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.Value of the clinical history for different users of dermoscopy compared with results of digital image analysis.Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline.Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis.Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients.Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight.Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumourMolecular diagnostics facilitate distinction between lethal and non-lethal subtypes of junctional epidermolysis bullosa: a case report and review of the literature.Surveillance and follow-up examinations in cutaneous melanoma.Systematic review of medical treatment in melanoma: current status and future prospects.Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC studyHuman melanoma progression in skin reconstructs : biological significance of bFGF.Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?Digital image analysis for diagnosis of cutaneous melanoma. Development of a highly effective computer algorithm based on analysis of 837 melanocytic lesions.The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression AnalysisSurveillance of patients at high risk for cutaneous malignant melanoma using digital dermoscopy.Study protocol for a prospective, non-controlled, multicentre clinical study to evaluate the diagnostic accuracy of a stepwise two-photon excited melanin fluorescence in pigmented lesions suspicious for melanoma (FLIMMA study)Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.Dermatofibrosarcoma protuberans--an update.Cutaneous melanoma: baseline and ongoing laboratory evaluation.Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.Identification of genes specifically regulated in human melanoma cells.
P50
Q27852927-420BA3FD-ECBD-432C-B64B-C46E23B0195AQ28131634-3C04C7F5-BF4C-49B9-9B3C-D91F211F0250Q28203903-F5E52BF0-C319-4588-8804-8733AEE2B8AAQ28236749-7F9BDB30-3720-4C40-B020-3F49175252A5Q29620663-F8364CCD-AB1D-4219-AA4E-8F8AA57A6335Q31150157-DB41859F-3AA9-46E2-A981-5C739C86533AQ33340639-35A66682-8B44-4046-A9E2-C2FBDAF31B6DQ33414272-0F625DEA-519D-4259-A3DD-18CC2F495AB7Q33456746-E76E7D25-8698-4E9D-A053-1F000F4B5B18Q33691572-ECFA1553-D26D-4C23-8B98-4212A2E1D904Q33861875-4160F53F-250C-4A75-BA6C-9E68EE5F6C36Q33886847-E4089755-76E1-45C4-A17D-3A75B261605FQ33999619-1EFC9796-D346-49E9-8250-F2869A37BD6FQ34010098-C4C94FC8-7BA1-40DF-9484-BB699B132231Q34140267-D5B24F01-F2AB-4788-AEB9-1397C9991716Q34482926-B459EA5C-45C3-466E-BA39-9681E2C73273Q34487294-E0157943-714E-42B8-ACA6-9BBA5DB7FAB3Q34515007-4418B194-E8C2-46A8-8D24-9C54C73D75C0Q34551846-7841985F-D750-4014-B950-7640DCF8DFBAQ34671756-BE9AE08F-BDFB-45F7-BD8F-58C1942042DCQ34702316-FE14FAF0-CFD1-4888-83D2-9F5C401CA719Q34722224-841D3D30-45AB-470C-B5D1-736B9783265CQ34762654-C0562995-A7FD-4E9F-8B15-C62B29951ED0Q34794495-C4194E73-C0C7-4C11-8692-EB6534E5C4FDQ35007174-6913830C-C71D-4D1C-80FA-E63D2858D301Q35170242-52B2948F-D485-4359-B90E-F528B05C72B7Q35584299-63945851-22C0-41E3-B60D-D43E0197C4F9Q35603108-C3873417-5288-41AE-BEFB-AF44077824B4Q35611877-FE019F94-4370-4665-AFDA-101A0AA01038Q35793439-14DD6FDC-39AD-49B4-8F59-F9361AECBDE1Q35794989-C2DF4BD0-DB4F-4C2B-AC06-B4F0BA39FDB1Q35947351-97256EC2-9ECB-45C5-BFAD-4996B0469DE7Q35947544-2162FC66-4DBC-46FD-9A29-42BE16A7010EQ36012924-B7B27A87-8B53-48FA-8107-6589A274E41CQ36228928-8919A6A6-784A-407E-A95D-78F0CE101C29Q36256712-D68D6AAA-3DE1-4F01-A401-06727E381E41Q36309950-E603C6AD-0805-4C56-A6C0-323D8FC0E480Q36317101-F4AC4B76-FC6E-48D8-BA4B-65712447192AQ36371217-4EF8BDC8-0CC4-42D9-ACD4-EB9E4A3C5DCEQ36688741-904FBAA0-D9BB-4908-AEBD-8DAA10A5D215
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
Claus Garbe
@ast
Claus Garbe
@en
Claus Garbe
@es
Claus Garbe
@nl
type
label
Claus Garbe
@ast
Claus Garbe
@en
Claus Garbe
@es
Claus Garbe
@nl
prefLabel
Claus Garbe
@ast
Claus Garbe
@en
Claus Garbe
@es
Claus Garbe
@nl
P31
P496
0000-0001-8530-780X